These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 25952299

  • 1. Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate.
    Catalano A, Morabito N, Di Stefano A, Morini E, Basile G, Faraci B, Loddo S, Ientile R, Lasco A.
    J Endocrinol Invest; 2015 Aug; 38(8):859-63. PubMed ID: 25952299
    [Abstract] [Full Text] [Related]

  • 2. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Reginster JY, Pong A, Rosenberg E, Santora A, FOCUS-D Investigators.
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [Abstract] [Full Text] [Related]

  • 3. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.
    Morabito N, Catalano A, Gaudio A, Morini E, Bruno LM, Basile G, Tsiantouli E, Bellone F, Agostino RM, Piraino B, La Rosa MA, Salpietro C, Lasco A.
    J Bone Miner Metab; 2016 Sep; 34(5):540-6. PubMed ID: 26204844
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
    Kaufman JM, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis RM, Goemaere S, Josse R, Palacios S, Ringe JD, Felsenberg D, Boonen S.
    J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis.
    Abboskhujaeva LS, Ismailov SI, Alikhanova NM.
    Drugs R D; 2014 Dec; 14(4):315-24. PubMed ID: 25480348
    [Abstract] [Full Text] [Related]

  • 7. Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women.
    Atteritano M, Catalano A, Santoro D, Lasco A, Benvenga S.
    Endocrine; 2016 Jul; 53(1):305-12. PubMed ID: 26304851
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
    Reginster JY, Bruyère O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, Devogelaer JP.
    Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
    [Abstract] [Full Text] [Related]

  • 10. The relationship of vitamin D status to bone mineral density in an Italian population of postmenopausal women.
    Malavolta N, Pratelli L, Frigato M, Mulè R, Mascia ML, Gnudi S.
    Osteoporos Int; 2005 Dec; 16(12):1691-7. PubMed ID: 15959621
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 14. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.
    Bruyère O, Collette J, Rizzoli R, Decock C, Ortolani S, Cormier C, Detilleux J, Reginster JY.
    Osteoporos Int; 2010 Jun; 21(6):1031-6. PubMed ID: 19813043
    [Abstract] [Full Text] [Related]

  • 15. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.
    Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, Kurosawa H.
    Calcif Tissue Int; 2009 Nov; 85(5):398-404. PubMed ID: 19795092
    [Abstract] [Full Text] [Related]

  • 16. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 17. Effect of strontium ranelate on serum leptin and bone turnover markers in women with established postmenopausal osteoporosis.
    Bayhan I, Dogan NU, Ozaksit G, Uygur D, Ugurlu N, Ugur M.
    J Reprod Med; 2013 Jan; 58(7-8):319-23. PubMed ID: 23947082
    [Abstract] [Full Text] [Related]

  • 18. Favorable effect of dietary vitamin C on bone mineral density in postmenopausal women (KNHANES IV, 2009): discrepancies regarding skeletal sites, age, and vitamin D status.
    Kim YA, Kim KM, Lim S, Choi SH, Moon JH, Kim JH, Kim SW, Jang HC, Shin CS.
    Osteoporos Int; 2015 Sep; 26(9):2329-37. PubMed ID: 25906241
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis.
    Liu JM, Wai-Chee Kung A, Pheng CS, Zhu HM, Zhang ZL, Wu YY, Xu L, Meng XW, Huang ML, Chung LP, Hussain NH, Sufian SS, Chen JL.
    Bone; 2009 Sep; 45(3):460-5. PubMed ID: 19464401
    [Abstract] [Full Text] [Related]

  • 20. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X, Servitja S, Peña MJ, Prieto-Alhambra D, Nadal R, Mellibovsky L, Albanell J, Diez-Perez A, Tusquets I.
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.